| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. | Director | Ordinary Shares | 1,485,168 | $26,747,876 | $18.01 | 21 Oct 2022 | Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd |
| Keros Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 155,262 | $2,241,983 | $14.44 | 04 Jun 2025 | Indirect |
| LB PHARMACEUTICALS INC | Director | Common Stock | 1,411,681 | 12 Sep 2025 | Indirect | ||
| LB PHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 22,449 | 10 Sep 2025 | Direct | ||
| Eloxx Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 20,000 | 15 Jun 2022 | Direct | ||
| Keros Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 10,500 | 04 Jun 2025 | Direct | ||
| LB PHARMACEUTICALS INC | Director | Series C Preferred Stock | 0 | 12 Sep 2025 | Indirect | ||
| UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | 21 Oct 2022 | By Pontifax Cayman III Limited Partnership | ||
| UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | 21 Oct 2022 | By Pontifax (Israel) III Limited Partnership |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | 12 Sep 2025 | 3 | +$15,000,000 | 4 | Director | 16 Sep 2025, 16:15 |
| LBRX | LB PHARMACEUTICALS INC | 10 Sep 2025 | 1 | $0 | 4 | Director | 12 Sep 2025, 18:25 |
| LBRX | LB PHARMACEUTICALS INC | 10 Sep 2025 | 0 | $0 | 3 | Director, 10%+ Owner | 11 Sep 2025, 09:19 |
| KROS | Keros Therapeutics, Inc. | 04 Jun 2025 | 0 | $0 | 4/A | Director, 10%+ Owner | 11 Jun 2025, 07:30 |
| KROS | Keros Therapeutics, Inc. | 30 May 2024 | 1 | $0 | 4 | Director, 10%+ Owner | 03 Jun 2024, 16:15 |
| KROS | Keros Therapeutics, Inc. | 06 Jun 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 08 Jun 2023, 16:44 |
| KROS | Keros Therapeutics, Inc. | 29 Nov 2022 | 6 | -$0.7176 | 4 | Director, 10%+ Owner | 30 Nov 2022, 15:40 |
| URGN | UroGen Pharma Ltd. | 21 Oct 2022 | 3 | +$285,114 | 4/A | Director | 28 Feb 2023, 11:23 |
| URGN | UroGen Pharma Ltd. | 16 Jun 2022 | 2 | +$11,055 | 4 | Director | 28 Feb 2023, 11:21 |
| ELOX | Eloxx Pharmaceuticals, Inc. | 15 Jun 2022 | 1 | $0 | 4 | Director | 17 Jun 2022, 08:26 |
| URGN | UroGen Pharma Ltd. | 08 Jun 2022 | 2 | $0 | 4 | Director | 10 Jun 2022, 15:36 |
| URGN | UroGen Pharma Ltd. | 06 Jun 2022 | 2 | +$5,150 | 4/A | Director | 28 Feb 2023, 11:29 |
| KROS | Keros Therapeutics, Inc. | 01 Jun 2022 | 1 | $0 | 4 | Director, 10%+ Owner | 03 Jun 2022, 16:30 |
| KROS | Keros Therapeutics, Inc. | 01 Jun 2021 | 1 | $0 | 4 | Director, 10%+ Owner | 03 Jun 2021, 17:34 |
| ELOX | Eloxx Pharmaceuticals, Inc. | 19 May 2021 | 1 | $0 | 4 | Director | 20 May 2021, 16:10 |
| ELOX | Eloxx Pharmaceuticals, Inc. | 13 May 2021 | 4 | +$7,999,999 | 4 | Director | 17 May 2021, 07:02 |
| URGN | UroGen Pharma Ltd. | 25 Mar 2021 | 2 | +$5,150 | 4/A | Director | 09 Jun 2021, 13:46 |
| URGN | UroGen Pharma Ltd. | 25 Mar 2021 | 4 | +$11,055 | 4 | Director | 09 Jun 2021, 13:42 |
| KROS | Keros Therapeutics, Inc. | 07 Apr 2020 | 0 | $0 | 3/A | Director, 10%+ Owner | 30 Nov 2022, 15:36 |